A computer simulated cost-effectiveness model of fremanezumab for migraine found that it was cost effective versus no treatment. Researchers presented a poster about its cost-effectiveness for the prevention of chronic and episodic migraine at ISPOR 2019.
A computer simulated cost-effectiveness model of fremanezumab for migraine found that it was cost effective versus no treatment. Researchers presented a poster about its cost-effectiveness for the prevention of chronic (CM) and episodic migraine (EM) at ISPOR 2019.
Fremanezumab is a calcitonin gene-related peptide inhibitor (CGRP) and was approved last year by the FDA for the preventive treatment of migraine in adults. Migraine is characterized as either EM, defined as fewer than 15 headache days per month, or CM, defined as 15 or more headache days per month for more than 3 months, of which 8 or more migraine days.
The Institute for Clinical and Economic Review (ICER) released its final evidence report evaluating the effectiveness and value of CGRP inhibitors last year, finding that fremanezumab fell under the $150,000 per quality-adjusted life year (QALY) threshold in CM and were nearly equivalent to the threshold in EM.
In the base case analysis, data from the pivotal fremanezumab randomized clinical trials (RCTs) were used for effectiveness, assuming that placebo had no effect on the number of migraine days (MDs).
Another analysis compared fremanezumab with placebo arm MD profiles (with placebo effect) based on RCT data.
Analyses were performed on a population made up of both patient groups (67% CM, 33% EM). Outcome measures were costs, reduction in MDs, and quality-adjusted life-years (QALYs); incremental cost-effectiveness ratios (ICERs) were reported as cost per QALY gained between fremanezumab and no treatment (placebo).
Three types of analyses were performed in the model: a deterministic ICER analysis, a 1-way sensitivity analysis, and a probabilistic sensitivity analysis (PSA). A semi-Markov cost-effectiveness model (CEM) was developed with a 4-week cycle and 10-year analysis time horizon. Costs and benefits were discounted at 3% annual rates. Treatment efficacy was incorporated as reduction in mean MDs/28 days. Patient cohorts were distributed among MD categories (0-28 MDs/28 days) based on mean MD levels.
The CEM estimated costs (fremanezumab acquisition and MD-related costs [direct and indirect]) and health-related quality of life (MD- and treatment status—based utilities) for fremanezumab and no-treatment arms.
Only background mortality was modeled. Outcome measures were costs, reduction in MDs, and quality-adjusted life-years (QALYs). The incremental cost-effectiveness ratio (ICER) was reported as cost/QALY gained between fremanezumab and no treatment. In the base-case analysis, randomized clinical trial (RCT) fremanezumab MDs/28 days were compared with constant no-treatment MD profiles. Fremanezumab was also compared with RCT-sourced placebo-arm MD profiles.
In the base-case 10-year analysis time horizon, monthly fremanezumab treatment resulted in a cost/QALY ICER of $17,755, with average incremental costs of $3642/patient, incremental QALYs of 0.205, and a 146-day reduction in MDs. Excluding indirect costs, fremanezumab treatment resulted in a cost/QALY ICER of $44,748, with average incremental costs of $9180/patient. Where placebo effects were included, fremanezumab treatment resulted in a cost/QALY ICER of $114,259, with average incremental costs of $10,491/patient, incremental QALYs of 0.092, and a 46.8-day reduction in MDs. Similar results were achieved using cost estimates for quarterly dosing.
Reference
Smolen L, Gandhi SK, Klein T, et al. 10-year cost-effectiveness analyses of fremanezumab as preventive treatment in chronic and episodic migraine. Presented at: ISPOR 2019 Annual Meeting, New Orleans, Louisiana; May 18-22, 2019; Poster PND21.
New Insights on Breast Cancer Outcomes Among Sexual, Gender Minorities
December 7th 2023Despite there being a great demand for data collection on sexual orientation and gender identity in the cancer space, individuals who identify as a sexual and gender minority remain poorly represented.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Race/Ethnicity May Influence Local Recurrence in DCIS, Adjuvant Treatment
December 6th 2023Disparities in 10-year local recurrence following breast-conserving surgery were seen among women with ductal carcinoma in situ (DCIS) treated over a nearly 4-decade span at Memorial Sloan Kettering Cancer Center, with Black women having the highest rate.
Read More
SDOH in Cancer Care Highlight Multifactorial Equity Issues
December 6th 2023A trio of speakers addressed the importance of social determinants of health (SDOH) in cancer care on day 1 of the 46th annual San Antonio Breast Cancer Symposium in the session, “Social Determinants of Health: Impact on Cancer Care.”
Read More